Insider Buying: NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Director Acquires 83,175 Shares of Stock

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) Director Group L. P. Column purchased 83,175 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was bought at an average price of $10.79 per share, for a total transaction of $897,458.25. Following the transaction, the director now directly owns 902,090 shares in the company, valued at $9,733,551.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of NASDAQ:NGM opened at $10.58 on Thursday. The business’s 50 day simple moving average is $14.87 and its 200-day simple moving average is $16.53. The firm has a market capitalization of $838.54 million, a price-to-earnings ratio of -6.53 and a beta of 1.79. NGM Biopharmaceuticals, Inc. has a 12 month low of $10.49 and a 12 month high of $30.13.

NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. NGM Biopharmaceuticals had a negative return on equity of 35.35% and a negative net margin of 162.11%. On average, sell-side analysts expect that NGM Biopharmaceuticals, Inc. will post -2.13 EPS for the current year.

Several equities analysts recently issued reports on NGM shares. Raymond James cut NGM Biopharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Wednesday, March 2nd. Zacks Investment Research upgraded NGM Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 9th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $31.57.

Several large investors have recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its stake in NGM Biopharmaceuticals by 128.5% in the 4th quarter. Point72 Asset Management L.P. now owns 3,297,898 shares of the company’s stock valued at $58,406,000 after buying an additional 1,854,904 shares in the last quarter. BlackRock Inc. lifted its stake in NGM Biopharmaceuticals by 13.7% in the 4th quarter. BlackRock Inc. now owns 2,780,791 shares of the company’s stock valued at $49,250,000 after buying an additional 335,959 shares in the last quarter. StepStone Group LP purchased a new stake in NGM Biopharmaceuticals in the 3rd quarter valued at approximately $33,072,000. Geode Capital Management LLC lifted its stake in NGM Biopharmaceuticals by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 697,974 shares of the company’s stock valued at $12,361,000 after buying an additional 54,101 shares in the last quarter. Finally, State Street Corp lifted its stake in NGM Biopharmaceuticals by 8.7% in the 4th quarter. State Street Corp now owns 675,380 shares of the company’s stock valued at $11,961,000 after buying an additional 54,217 shares in the last quarter. 58.50% of the stock is currently owned by institutional investors and hedge funds.

NGM Biopharmaceuticals Company Profile (Get Rating)

NGM Biopharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH.

Featured Articles